Targeted agents and combinations at ENA 2026

Nov 18–20, 2026 Barcelona, Spain ~1.5k attendees Website

98 organizations at ENA 2026 present work in molecular targeted agents, combinations and drug resistance, led by drug developers. Between them they bring 200 presentations to the program. Most represented: MD Anderson Cancer Center, Vall d'Hebron Institute of Oncology (VHIO) and National Cancer Institute (NCI). As of Oct 13, 2026.

All 254 organizations at ENA 2026 →

Showing 1–5 of 98 organizations

Organization	ENA 2026 Attendance
MD Anderson Cancer Center Houston, Texas
mdanderson.org Cancer centres & hospitals University of Texas cancer centre for patient care, research and early-phase clinical trials.	Session Wed Nov 18 4:15–5:45pm Workshop 2: Radiopharmaceuticals ADCs & radioligands Talk Wed Nov 18 4:55–5:15pm Part of Workshop 2: Radiopharmaceuticals Translating Radiopharmaceutical Innovation from Bench to Bedside ADCs & radioligands Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Antibody-drug conjugates Translational validation of uPARAP (MRC2) as an antibody–drug conjugate target in osteosarcoma patient-derived xenograft models ADCs & radioligands Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Antibody-drug conjugates Preliminary phase 1 results from AVENTINE-1, a phase 1/2 study of AVZO-1418, an EGFR-HER3 bispecific antibody-drug conjugate (BsADC) for the treatment of patients with locally advanced or metastatic solid tumors ADCs & radioligands Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Antibody-drug conjugates Population pharmacokinetics (popPK) and exposure-response analyses of sacituzumab tirumotecan (sac-TMT) antibody-drug conjugate (ADC) in participants (pts) with advanced solid tumors ADCs & radioligands Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Drug Resistance and Modifiers TROP2 Predicts Response to TUSC2 Gene Therapy (Quaratusugene Ozeplasmid) and Its Modulation Sensitizes Non-Small Cell Lung Cancer to Treatment Targeted agents Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Translational Studies Targeting the PI4K2A lysosomal pathway is a promising approach for lung cancer therapy Biomarkers Talk Thu Nov 19 10–10:10am Part of Plenary Session 3: Proffered Papers Phase 1 trial and translational study of the glutaminase-1 (GLS1) inhibitor IACS-6274 in combination with bevacizumab and paclitaxel in patients with advanced ovarian cancer Early clinical · Targeted agents Session Thu Nov 19 2–2:30pm Posters in the Spotlight, session 1 Session Thu Nov 19 3–4:30pm Workshop 3: End-to-End Early Clinical Development Through AI AI · Early clinical Session Thu Nov 19 3–4:30pm Workshop 4: Next-Generation Precision Oncology: Progress, Pitfalls and Promise Genomics Talk Thu Nov 19 3:20–3:40pm Part of Workshop 3: End-to-End Early Clinical Development Through AI Radiology - Digital twins and multiomics AI · Early clinical Talk Thu Nov 19 3:40–4pm Part of Workshop 4: Next-Generation Precision Oncology: Progress, Pitfalls and Promise Rewiring the Cell Cycle: Early Clinical Insights from Next-Generation Cyclin and CDK Targeting Genomics Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: Drug Delivery A Bayesian pharmacokinetics-integrated Phase I–II design to optimize dose-schedule regimes Drug design Talk Fri Nov 20 3–3:10pm Part of Plenary Session 7: Proffered papers Interim results from the ﬁrst-in-human phase 1 study of WEE1 inhibitor APR-1051 in patients with advanced solid tumors (ACESOT-1051) Early clinical · Targeted agents Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: Combination Therapies Discovery of novel combination strategies to target SWI/SNF mutant lung cancers Targeted agents
Vall d'Hebron Institute of Oncology (VHIO) Barcelona, Spain
vhio.net Cancer centres & hospitals Barcelona cancer research institute at Vall d'Hebron University Hospital, combining translational research with an early-phase clinical trials unit.	Session Wed Nov 18 1:30–1:35pm Opening Ceremony: Welcome and opening of the ENA 2026 Symposium Session Wed Nov 18 1:35–2:20pm Keynote Lecture: The rise of biotech in APAC Session Wed Nov 18 2:20–3:50pm Plenary Session 1: The next wave of immune engagers in cancer therapy: beyond CD3 and beyond T cells Immuno-oncology Talk Thu Nov 19 3:20–3:40pm Part of Workshop 4: Next-Generation Precision Oncology: Progress, Pitfalls and Promise Targeting YAP/TEAD as monotherapy and in rational combinations Genomics Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: Molecular Targeted Agents Phase Ib study of OMO-103 in combination with gemcitabine and nab-paclitaxel in first-line metastatic pancreatic ductal adenocarcinoma Targeted agents Session Fri Nov 20 8–9:30am Plenary Session 5: Next-generation cell therapies (CAR-T, TCR) Cell therapy Talk Fri Nov 20 8:40–9am Part of Plenary Session 5: Next-generation cell therapies (CAR-T, TCR) Neoantigen TCR-T Cell therapy Talk Fri Nov 20 9:45–10am Part of Workshop 7: Novel Methodologies & Endpoints in New Drug Development Multi-omics including Spatial Transcriptomics Early clinical Talk Fri Nov 20 12–12:10pm Part of Plenary Session 6: Proffered papers MYC Inhibition with OMO-103 Restores TNF-Superfamily Signaling and Uncovers Actionable Immunotherapy Vulnerabilities in KRAS-Mutant NSCLC Targeted agents · Immuno-oncology Session Fri Nov 20 3–4:50pm Plenary Session 7: Proffered papers Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: Novel clinical trial design Digital Remote Patient Monitoring in Early-Phase Oncology Clinical Trials: A Prospective Pilot Study of Feasibility and Implementation Early clinical Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: Preclinical Models A preclinical patient-derived xenograft platform to model resistance to cyclin-dependent kinase 4/6 inhibitors plus endocrine therapy in oestrogen receptor-positive breast cancer. Preclinical models Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: Preclinical Models Integrative molecular profiling of a breast cancer (BC) patient-derived xenograft (PDX) platform for biomarker discovery Preclinical models
National Cancer Institute (NCI) Bethesda, Maryland
cancer.gov Agencies, groups & societies Federal agency within NIH that funds and conducts cancer research, including intramural labs and clinical trials.	Session Wed Nov 18 1:30–1:35pm Opening Ceremony: Welcome and opening of the ENA 2026 Symposium Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Drug Resistance and Modifiers Comparison of CRISPR screens in two- and three-dimensional ovarian cancer models to identify architecture-dependent mechanisms of resistance to CHEK1 inhibition Targeted agents Session Thu Nov 19 10–11:30am Plenary Session 3: Proffered Papers Session Thu Nov 19 5–6:30pm Workshop 6: Tumour microenvironment Immuno-oncology Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: New therapies in immuno oncology A novel virus-like drug conjugate for the treatment of cutaneous melanoma Immuno-oncology Session Fri Nov 20 8–9:30am Plenary Session 5: Next-generation cell therapies (CAR-T, TCR) Cell therapy Session Fri Nov 20 11:15am–12pm Keynote lecture: Immunotherapy innovations Immuno-oncology Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: Combination Therapies ClpP Agonist-Induced Cellular Senescence Promotes Vulnerability to Apoptosis and Ferroptosis in Triple Negative Breast Cancers Targeted agents
Crown Bioscience San Diego, CA
crownbio.com CROs & CDMOsExhibitor Preclinical oncology CRO offering patient-derived xenograft, organoid and syngeneic models plus translational and biomarker services.	Booth Exhibiting at Booth 30 Wed, Nov 1812–7pmThu, Nov 199am–5:30pmFri, Nov 209am–3pm Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Drug Resistance and Modifiers Developing Different Preclinical RAS Inhibitor Resistant Xenograft Models for Next-Generation Therapeutic Evaluation Targeted agents Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: Molecular Targeted Agents Integrated Organoid Screening Approaches Enable Preclinical Assessment of Targeted Protein Degrader Efficacy and Target Engagement Targeted agents Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: Animal Models Characterization of a Panel of PDX Models Derived from c-MET Targeting ADCs Pretreated Colorectal Cancer Patients for Therapeutic Evaluation Preclinical models Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: Animal Models Establishing Preclinical Mouse Models for Translational Cancer Cachexia Research Preclinical models Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: Preclinical Models End-to-end in vitro and in vivo evaluation of radiopharmaceuticals in patient-derived models Preclinical models Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: Preclinical Models Benchmarking Multiple Comparison Procedures for Patient-Derived Xenograft Tumor-Volume Studies: Toward Statistically Justified and Ethically Grounded Study Design Preclinical models Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: Preclinical Models PDX-Derived Organoids Demonstrate High Concordance with In Vivo Responses Across KRAS Inhibitors and Antibody-Drug Conjugates Preclinical models
Memorial Sloan Kettering Cancer Center New York, NY
mskcc.org Cancer centres & hospitals Cancer treatment and research centre with clinical, laboratory and computational research programmes.	Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Drug Resistance and Modifiers A super glue to trap wild-type and mutant variants of the ARAF:MEK1 complex Targeted agents Talk Thu Nov 19 8–8:25am Part of Plenary Session 2: RAS pathway: "Targeting RAS - What's Next?" Brief clinical overview, mechanistic insights into resistance and RBD mutation studies Targeted agents Talk Thu Nov 19 4–4:20pm Part of Workshop 3: End-to-End Early Clinical Development Through AI Therapeutic selection – drug design and protein folding AI · Early clinical Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: New agents for paediatric oncology Safety and efficacy of autologous tumor infiltrating lymphocyte therapy in pediatric and adolescent patients with immune checkpoint inhibitor-refractory metastatic melanoma: Results from a phase I clinical trial Targeted agents Talk Fri Nov 20 12:15–12:25pm Part of Plenary Session 6: Proffered papers ARV-806, a PROTAC KRAS G12D Degrader, in Patients With KRAS G12D–Mutated Advanced Solid Tumors: Preliminary Phase 1 Results Drug design · Early clinical